KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major
- PMID: 19162111
- DOI: 10.1016/j.vaccine.2008.12.053
KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major
Abstract
As vaccine potential of cross-species protection by a candidate antigen is less explored, in this study we compared cross-specific protective efficacy of Kinetoplastid Membrane Protein-11 (KMP-11) as a DNA vaccine alone and in conjunction with exogenous IL-12 administration in experimental BALB/c model against two most widely prevalent forms of clinical diseases caused by Leishmania major (LM) and Leishmania donovani (LD). Whereas, KMP-11 DNA vaccination alone showed significant potential in terms of resolution of splenic and hepatic parasite burden against virulent LD challenge, it showed considerably less efficacy (<70% reduction) against virulent LM challenge in terms of presence of parasite in lymph node. Remarkably exogenous IL-12 administration in the form of IL-12 p35/p40 expression vectors or recombinant protein along with KMP-11 DNA had exactly opposing effect on protection against LM and LD. Exogenous IL-12 administration significantly increased residual LD-burden but enhanced the protective efficacy of KMP-11 DNA vaccine against LM compared to KMP-11 immunization alone. Elucidation of effector mechanism showed KMP-11 DNA induced protection against LD was associated with the generation of mixed Th1/Th2 response, while KMP-11/IL-12-induced comparable protection against LM was associated with high IgG2a titre indicative of a polarized Th1 response. Exogenous IL-12 administration resulted in robust gamma interferon (IFN-gamma) production and suppression of IL-4 from CD4+ T cell against both LM and LD. Nevertheless protective immune response was only compromised against LD infection where frequency of anti-KMP-11 CTL response was significantly reduced after exogenous IL-12 administration. Our study provides a comparative evaluation of effector mechanisms in the assessment of cross-specific protection by KMP-11 and KMP-11/IL-12 immunization against these two prevalent forms of leishmaniasis.
Similar articles
-
Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.Infect Immun. 2001 Aug;69(8):4719-25. doi: 10.1128/IAI.69.8.4719-4725.2001. Infect Immun. 2001. PMID: 11447143 Free PMC article.
-
Cellular vaccination with bone marrow-derived dendritic cells pulsed with a peptide of Leishmania infantum KMP-11 and CpG oligonucleotides induces protection in a murine model of visceral leishmaniasis.Vaccine. 2011 Jul 12;29(31):5053-64. doi: 10.1016/j.vaccine.2011.04.089. Epub 2011 May 11. Vaccine. 2011. PMID: 21569815
-
Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.Eur J Immunol. 2009 Aug;39(8):2146-60. doi: 10.1002/eji.200839017. Eur J Immunol. 2009. PMID: 19593771
-
Kinetoplastid Membrane Protein-11 as a Vaccine Candidate and a Virulence Factor in Leishmania.Front Immunol. 2015 Oct 13;6:524. doi: 10.3389/fimmu.2015.00524. eCollection 2015. Front Immunol. 2015. PMID: 26528287 Free PMC article. Review.
-
Interleukin-10 and the pathogenesis of human visceral leishmaniasis.Trends Immunol. 2007 Sep;28(9):378-84. doi: 10.1016/j.it.2007.07.004. Epub 2007 Aug 6. Trends Immunol. 2007. PMID: 17689290 Review.
Cited by
-
Vaccination in Leishmaniasis: A Review Article.Iran Biomed J. 2022 Jan 1;26(1):1-35. doi: 10.52547/ibj.26.1.35. Iran Biomed J. 2022. PMID: 34952558 Free PMC article.
-
Development of the Antileishmanial Vaccine.Methods Mol Biol. 2022;2410:433-461. doi: 10.1007/978-1-0716-1884-4_23. Methods Mol Biol. 2022. PMID: 34914062
-
Effect of Prophylactic Vaccination with the Membrane-Bound Acid Phosphatase Gene of Leishmania mexicana in the Murine Model of Localized Cutaneous Leishmaniasis.J Immunol Res. 2021 Apr 9;2021:6624246. doi: 10.1155/2021/6624246. eCollection 2021. J Immunol Res. 2021. PMID: 33928168 Free PMC article.
-
LmjF.36.3850, a novel hypothetical Leishmania major protein, contributes to the infection.Immunology. 2021 Aug;163(4):460-477. doi: 10.1111/imm.13331. Epub 2021 Apr 26. Immunology. 2021. PMID: 33764520 Free PMC article.
-
Immunization against Leishmania major infection in BALB/c mice using a subunit-based DNA vaccine derived from TSA, LmSTI1, KMP11, and LACK predominant antigens.Iran J Basic Med Sci. 2019 Dec;22(12):1493-1501. doi: 10.22038/IJBMS.2019.14051. Iran J Basic Med Sci. 2019. PMID: 32133069 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials